Form 4 Structure Therapeutics Inc ADR For: 24 July
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Structure Therapeutics Inc ADR (GPCR)
Track today's live Structure Therapeutics ADR (GPCR) share price, performance and key data on this page with our current NASDAQ:GPCR stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Structure Therapeutics ADR share price on the NASDAQ exchange. Use the dropdown to switch exchange for the GPCR share price, head to our technical summary section, which provides analysis on Structure Therapeutics ADR share price buy/sell indicators using real-time data (or discuss the Structure Therapeutics ADR (GPCR) stock price today with other investors in the Structure Therapeutics ADR NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:GPCR share price (ISIN: US86366E1064) to enhance your trading decisions with our free investment tools and resources.
What Is the Structure Therapeutics Inc ADR Share Price Today?
The Structure Therapeutics ADR share price today is 49.64.
What Is the Stock Symbol for Structure Therapeutics Inc ADR
The stock symbol (or 'ticker') for Structure Therapeutics Inc ADR is "GPCR."
What Stock Exchange Does Structure Therapeutics Inc ADR Trade On?
Structure Therapeutics Inc ADR is listed and trades on the NASDAQ stock exchange.
Is Structure Therapeutics Inc ADR a Good Stock to Buy?
Determining whether Structure Therapeutics ADR (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:GPCR share price (ISIN: US86366E1064) to enhance your trading decisions with our free investment tools and resources.
What Is the Structure Therapeutics Inc ADR Share Price Today?
The Structure Therapeutics ADR share price today is 49.64.
What Is the Stock Symbol for Structure Therapeutics Inc ADR
The stock symbol (or 'ticker') for Structure Therapeutics Inc ADR is "GPCR."
What Stock Exchange Does Structure Therapeutics Inc ADR Trade On?
Structure Therapeutics Inc ADR is listed and trades on the NASDAQ stock exchange.
Is Structure Therapeutics Inc ADR a Good Stock to Buy?
Determining whether Structure Therapeutics ADR (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.30
50.51
52 wk Range
15.80
94.90
Earnings results expected tomorrow
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.3050.51
52 wk Range
15.8094.90
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GPCR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
104.83
Upside
+111.19%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 4 Structure Therapeutics Inc ADR For: 15 July- Investing.com
Form 4 Structure Therapeutics Inc ADR For: 29 June- Investing.com
- Form 4 Structure Therapeutics Inc ADR For: 24 July
- Investing.com
- Form 4 Structure Therapeutics Inc ADR For: 15 July
- Investing.com
- Form 4 Structure Therapeutics Inc ADR For: 29 June
- Investing.com
Form 144 Structure Therapeutics Inc. For: 25 June- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
14 Buy
1 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 104.83
(+111.19% Upside)
Structure Therapeutics Inc ADR SWOT Analysis
Oral GLP-1 Pionee | Structure Therapeutics leads the charge in developing oral treatments for diabetes and obesity, with aleniglipron showing promise in the competitive GLP-1 market |
Pipeline Potential | Explore GPCR's robust pipeline, including aleniglipron and ACCG-2671, poised to disrupt the metabolic disease treatment landscape with oral formulations |
Market Dynamics | Delve into Structure Therapeutics' strategic positioning amidst fierce competition from pharma giants, leveraging its focus on oral small molecule therapies |
Financial Outlook | Analyst price targets range from $37.50 to $120 per share, reflecting optimism about GPCR's potential in the expanding GLP-1 receptor agonist market |
Earnings
Latest Release
07/05/2026
EPS / Forecast
-0.35 / -0.35
Revenue / Forecast
-- / --
Compare GPCR to Peers and Sector
Metrics to compare | GPCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGPCRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −20.7x | −20.6x | −0.4x | |
PEG Ratio | 4.55 | −0.09 | 0.00 | |
Price/Book | 2.4x | 3.2x | 2.6x | |
Price / LTM Sales | - | 11.8x | 3.0x | |
Upside (Analyst Target) | 108.9% | 33.1% | 51.9% | |
Fair Value Upside | Unlock | −1.0% | 7.2% | Unlock |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Structure Therapeutics ADR (NASDAQ: GPCR) Share Price Today?
The Structure Therapeutics ADR stock price today is 49.64 USD.
What Stock Exchange Does Structure Therapeutics ADR (GPCR) Trade On?
Structure Therapeutics ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Structure Therapeutics ADR?
The stock symbol (also called a 'ticker') for Structure Therapeutics ADR is "GPCR."
What Is the Current Structure Therapeutics ADR Market Capitalisation?
As of today, Structure Therapeutics ADR (NASDAQ: GPCR) market cap is 3.53B USD.
What Is Structure Therapeutics ADR's (GPCR) Earnings Per Share (TTM)?
The Structure Therapeutics ADR EPS is currently -2.71 (Trailing Twelve Months).
When Is the Next Structure Therapeutics ADR Earnings Date?
Structure Therapeutics ADR's next earnings report will be released on 06/08/2026.
Is GPCR a Buy or Sell From a Technical Analyst Perspective?
Based on today's Structure Therapeutics ADR moving averages and other technical indicators, the daily buy/sell signal for GPCR stock is Strong Buy.
How Many Times Has Structure Therapeutics ADR Stock Split?
Structure Therapeutics ADR has split 0 times. (See the GPCR stock split history page for full effective split date and price information.)
How Many Employees Does Structure Therapeutics ADR Have?
Structure Therapeutics ADR has 233 employees, based on their latest Companies House report.
What is the current trading status of Structure Therapeutics ADR (NASDAQ: GPCR)?
As of 05/08/2026, Structure Therapeutics ADR (GPCR) is trading at a share price of 49.64 USD, with a previous close of 48.36 USD. The stock has fluctuated within a day range of 48.30 USD to 50.51 USD, while its 52-week range spans from 15.80 USD to 94.90 USD.
What Is Structure Therapeutics ADR (GPCR) Price Target According to Analysts?
The average 12-month price target for Structure Therapeutics ADR is 104.83 USD, with a high estimate of 145 USD and a low estimate of 69.5 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +111.19% Upside potential.
What Is the GPCR Premarket Price?
GPCR's last pre-market stock price is 49.87 USD. The pre-market share volume is 526.00, and the stock has decreased by 1.51, or 3.12%.
What Is the GPCR After Hours Price?
GPCR's last after hours stock price is 50.05 USD, the stock has decreased by 0.41, or 0.83%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.